HF-158K1 by HighField Biopharmaceuticals for Colon Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Colon Cancer.

Parents struggle to monitor teens’ caffeine intake, national poll reveals

A quarter of parents report that caffeine is basically part of their teen’s daily life, according to a national poll.

May 20, 2024

RareStone narcolepsy therapy receives approval in China

Pitolisant is indicated to treat excessive daytime sleepiness in adult narcolepsy patients. Credit: Vladislav Muslakov on Unsplash. The Chinese National Medical Products Administration (NMPA) has granted

July 5, 2023

Revolutionizing asthma care: AI-powered stethoscope for home monitoring of exacerbations

Study demonstrates the effectiveness of an AI-aided stethoscope, StethoMe, for remotely monitoring asthma exacerbations in both children and adults.

December 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.